Knowing that high IL-33 content is associated with initial stages of the disease progression and, at the same time, is favorable for ILC2 cell functionality, we performed an IHC study targeting eosinophils in human prostate tumors with high and low IL-33 content. This evidence concerns the gene IL33 and prostate neoplasm.